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Abstract 
Undesired immune responses have drastically hampered outcomes after allogeneic organ 
transplantation and cell therapy, and also lead to inflammatory diseases and autoimmunity. Umbilical 
cord mesenchymal stem cells (UCMSCs) have powerful regenerative and immunomodulatory potential, 
and their secreted extracellular vesicles (EVs) are envisaged as a promising natural source of 
nanoparticles to increase outcomes in organ transplantation and control inflammatory diseases. 
However, poor EV preparations containing highly-abundant soluble proteins may mask genuine 
vesicular-associated functions and provide misleading data. Here, we used Size-Exclusion 
Chromatography (SEC) to successfully isolate EVs from UCMSCs-conditioned medium. These vesicles 
were defined as positive for CD9, CD63, CD73 and CD90, and their size and morphology characterized 
by NTA and cryo-EM. Their immunomodulatory potential was determined in polyclonal T cell 
proliferation assays, analysis of cytokine profiles and in the skewing of monocyte polarization. In sharp 
contrast to the non-EV containing fractions, to the complete conditioned medium and to 
ultracentrifuged pellet, SEC-purified EVs from UCMSCs inhibited T cell proliferation, resembling the 
effect of parental UCMSCs. Moreover, while SEC-EVs did not induce cytokine response, the non-EV 
fractions, conditioned medium and ultracentrifuged pellet promoted the secretion of pro-inflammatory 
cytokines by polyclonally stimulated T cells and supported Th17 polarization. In contrast, EVs did not 
induce monocyte polarization, but the non-EV fraction induced CD163 and CD206 expression and 
TNF-α production in monocytes. These findings increase the growing evidence confirming that EVs are 
an active component of MSC’s paracrine immunosuppressive function and affirm their potential for 
therapeutics in nanomedicine. In addition, our results highlight the importance of well-purified and 
defined preparations of MSC-derived EVs to achieve the immunosuppressive effect. 
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Exacerbated immune responses drastically 
hamper outcomes in allogeneic cell and organ 
transplantation, and lead to autoimmune disorders 
causing morbidity and mortality. In this context, due 
to their regenerative and immunomodulatory 
capacities, mesenchymal stem cells (MSCs) have been 
proposed as powerful inhibitors to counteract such 
unwanted immune responses. Thus, MSCs represent 
a promising strategy for a variety of medical 
conditions, including treatment of damaged tissue, 
inflammatory diseases and transplantation [1,2]. 
MSCs comprise a population of multipotent 
progenitor cells that have been obtained from distinct 
human tissues [3]. In particular, MSCs can be isolated 
from several compartments of the umbilical cord such 
as umbilical cord blood, umbilical vein 
subendothelium and the Wharton’s jelly [4]. Our 
study is confined to the MSCs from the subamnion 
connective tissue surrounding the umbilical vessels or 
Wharton’s jelly (here namely UCMSC), which 
includes a primitive self-renewing cell population 
with the characteristics of MSCs defined by the 
International Society for Cellular Therapy [5]. While 
the immune capabilities of UCMSC have been poorly 
described yet, MSCs from bone marrow and adipose 
tissue have been suggested to acquire better 
immunosuppressive functions after encountering an 
inflammatory stimulus, such as in vitro priming by 
IFNγ [6–11]. Moreover, increasing evidence has 
shown that the restorative and immunosuppressive 
functions exerted by MSCs are both cell-contact 
dependent and also mediated through a variety of 
secreted soluble factors in a paracrine fashion, 
including tryptophan depletion by IDO, production 
of immunosuppressive molecules and cytokines such 
as adenosine, NO, PGE2, IL-10 and TGFβ [12–15] and 
also released extracellular vesicles (EVs) [16,17]. 
EVs are membrane nanovesicles, which range 
approximately from 30 to 200 nm, carrying molecules 
that reflect the phenotype and functions of the cells of 
origin [18]. To date, therapeutic applications of 
MSC-EVs include treatment of experimental acute 
and chronic kidney injury [19], reduction of 
ischemia/reperfusion injury [20] and 
Graft-versus-Host Disease suppression [21]. Taken 
together, these studies point to MSC-EVs as 
promising candidates for novel cell-free therapies 
[17,22]. In the context of bionanotechnology, however, 
there are still open questions regarding the best 
method of EV preparation and concentration, 
characterization in terms of biological activity [23,24], 
and definition of the underlying mechanisms of action 
for the standardization of EV preparations that can be 
used in the clinical setting [25]. These points, along 
with the reported non-beneficial effect of non-purified 
MSC conditioned medium (CM) itself [26,27], stress 
the need for refining more efficient MSC-EV 
preparations and characterize them in terms of 
immunomodulatory potential. 
Thus, in the present study, we examined the 
suppressive potential of Size-Exclusion 
Chromatography (SEC)-enriched EVs derived from 
UCMSCs and compared the data with the non-EV 
containing fractions, non-purified CM and its 
ultracentrifuged pellet (UC pellet). The presented 
results demonstrate that nanosized EVs retain the 
immunosuppressive effect of MSCs mainly by 
inhibiting T cell proliferation and preventing the 
secretion of pro-inflammatory cytokines by 
polyclonally stimulated T cells. 
Results 
UCMSCs characterization 
Primary cultures of elongated fibroblast-like 
cells established from UC were recognized as bona 
fide MSCs when evaluated by flow cytometry and in 
differentiation assays. In particular, over 95% of cells 
expressed a MSC-like profile, being positive for 
CD105, CD44, CD166, CD10, CD73, CD90, CD49c, 
CD49d, CD49e, and HLA-ABC, and negative for 
CD117, CD106, CD34, CD45, CD29, CD14, CD133, 
CD31, VEGFR2 and HLA-DR. Moreover, commitment 
of cells to the adipogenic, osteogenic and 
chondrogenic pathways resulted in accumulation of 
intracellular lipid droplets, in high extracellular 
deposition of calcium and in active synthesis of 
proteoglycans, respectively (Figure S1). 
We subsequently explored the influence of IFNγ 
priming on the MSC’s phenotype. As shown in Figure 
1A, cultured cells had a typical spindle-shaped 
morphology regardless of IFNγ priming. In terms of 
MSC markers, 48h-IFNγ conditioning lead to 
unchanged CD73 and decreased CD90 levels, while 
MHC class II expression (HLA-DR) was significantly 
increased (Figure 1B,1C). 
UCMSCs suppress T cells proliferation 
It has been widely shown that MSCs from 
different origins inhibit T cell proliferation. To 
determine whether human UCMSC possess this 
capability and to analyze the influence of IFNγ 
priming on these cells, T cells were stimulated in the 
presence of increasing numbers of unconditioned or 
IFNγ-conditioned UCMSCs. The results confirmed 
that UCMSCs were able to inhibit polyclonal T cell 
proliferation and only at extremely low UCMSC:T cell 
ratios this effect was lost (Figure 1D). Our 
experiments showed that IFNγ-conditioning did not 





change their immune regulatory capabilities, as the 
reduced T cell proliferation was similar to the 
unconditioned UCMSCs. In these experiments T cell 
viability was not affected (Figure 1E). 
Isolation and characterization of EVs from 
UCMSCs 
After confirming the immunosuppressive 
potential of UCMSCs, we aimed to investigate 
whether EVs could be a mediator of the paracrine 
immunosuppressive action. First, EVs produced by 
UCMSCs were enriched from concentrated 
48h-Conditioned Medium (CCM) by SEC (Figure 2A). 
EVs were found in fractions 5 to 7 according to their 
positivity for the EV-associated tetraspanins CD9 and 
CD63 (Figure 2B, C). The MSC markers CD73 (70 kDa) 
and CD90 (25-37 kDa) co-eluted in the EV fractions 
(F5-7), suggesting their presence in EVs as recently 
published [28]. Bulk protein content of CCM was 
detected from fraction 9 onwards. Of note, CCM from 
both IFNγ-conditioned and unconditioned UCMSCs 
showed the same SEC elution pattern, in which EVs 
were successfully separated from the bulk of protein. 
In this scenario, three distinct pools of SEC fractions 
were collected for further studies: i) the EV fraction, a 
pool of the tetraspanin-peak fractions (“EV”; F5-7); ii) 
the early tetraspanin-negative fractions, pooled as the 
proximal non-EV fractions (“non-EV prox”; F10-11); 
and iii) the late tetraspanin-negative fractions, pooled 
as the distal non-EV fractions (“non-EV dist”; F13-14).  
 
 
Figure 1. A: Bright-field images of UCMSC in culture media without (left) or with IFNγ (right). Scale bars = 100 µm. B-C: UCMSCs primed with IFNγ expressed unchanged 
levels of CD73, lower levels of CD90 and higher levels of HLA-DR (class II MHC) on surface. B: Representative histograms of unconditioned (blue line) and IFNγ-primed 
UCMSCs (red line) labeled for CD73, CD90 and HLA-DR. Isotype controls are depicted as shaded areas. C: MFI values for CD73, CD90 and HLA-DR of UCMSCs after culture 
without (white circles) or with IFNγ (black circles). Data is shown for nine independent experiments. ***p<0.001 by Paired T test; **p<0.01 by Wilcoxon matched-pairs signed 
rank test. D-E: Proliferation and viability of T cells stimulated with anti-CD2/CD3/CD28 coated microbeads in the absence or presence of unconditioned or IFNγ-primed 
UCMSCs at 1:15, 1:60, 1:240, 1:480, 1:960 or 1:1,920 cell ratios were analyzed by CFSE loss and FSC/SSC gating, respectively. D: Bars represent means ±SD of proliferation 
relative to their PBS control. E: Bars represent means ± SD of the percentage of viable cells. Data accounts for seven independent experiments from different donor samples, 
performed in triplicates. Statistical differences are indicated for groups with *p<0.05 and **p<0.01 by One sample T test to the 100%. 
 






Figure 2. EVs were successfully isolated by SEC. A: Scheme of the methodological procedure followed for the generation of the different study fractions obtained from UCMSC 
48h-culture: supernatant was cleared of debris by centrifugation to obtain conditioned media (CM); concentrated CM (CCM) and eluted CM (ECM) were collected after 
ultrafiltration; CCM was loaded to the SEC column and fractions collected. B-C: UCMSC-EVs were found on fractions 5-7 while protein eluted after fraction 8 on both samples 
coming from unconditioned (B) and IFNγ-conditioned UCMSCs (C). SEC eluted fractions were checked for EV markers (CD9 and CD63), MSC markers (CD73 and CD90) by 
bead-based flow cytometry (left axis). Protein elution was monitored by absorption at 280nm (right axis). D-E: Cryo-EM images confirmed UCMSC-EVs presence in pooled EV 
fractions (F5-7) of unconditioned (D) and IFNγ-conditioned SEC preparations (E). Images of 20,000x and 30,000x magnifications are shown, with 200nm and 100nm scale bars, 
respectively. F: Box plot of the fold increase in protein content, CD9 and CD63 MFI of pooled EV fractions obtained from IFNγ-primed UCMSCs relative to unconditioned 
UCMSCs. Medians of ten independent experiments are depicted as horizontal bars, outliers as points. G: CD73, CD90, HLA-ABC (MHC-I) and HLA-DR (MHC-II) expression 
on EVs from unconditioned (white dots) and corresponding IFNγ-primed MSCs (black dots) are shown normalized to their CD9 MFI. Each dot corresponds to an independent 
experiment (n=10 and 6). 
 
Subsequently, in order to confirm the presence of 
EVs, SEC fractions were processed for cryo-electron 
microscopy (cryo-EM) and analyzed by nanoparticle 
tracking analysis (NTA). EV fractions were confirmed 
to contain round-shaped nanovesicles free of 
contaminating clumps or protein aggregates by 





cryo-EM (Figure 2D, E and Figure S2A). NTA analysis 
of the tetraspanin-peak fractions showed the presence 
of particles with a mode diameter of 169.6 and 157.2 
nm for unconditioned and IFNγ-primed 
UCMSC-EVs, respectively (Figure S2B). On the other 
hand, NTA indicated the presence of particles with a 
modal size of 118.1 nm in the proximal and 155.1 nm 
in the distal non-EV fractions, but cryo-EM images 
confirmed the lack of EVs in those fractions (Figure 
S2B). Overall, the concentration of particles calculated 
by NTA (regardless the presence or not of EVs) was 
very similar among all the experiments, ranging 
2-6x1010 particles/ml (Figure S2A). 
Analyses of the effect of IFNγ priming on EV 
production showed similar protein content, 
CD9 and CD63 presence and particle 
concentration in EV-containing SEC fractions 
(Figure 2F and Figure S2A). MFI values were 
then normalized to the expression of CD9 
and, unlike the results observed in cells, HLA 
molecules remained absent in the majority of 
EV batches after IFNγ priming. Regarding 
MSC markers, CD73 was unchanged and 
CD90 decreased, resembling parental cells’ 
behavior (Figure 2G). 
Due to the apparent insubstantial 
benefits of IFNγ priming on the 
immunomodulatory capacities of UCMSCs, 
these would not recommend using 
IFNγ-priming on UCMSCs, especially in the 
allogeneic delivery setting given the 
HLA-DR overexpression in UCMSCs, also 
observed in few MSC-EV batches. 
UCMSC-EVs reduce T cell 
proliferation and inflammatory 
cytokine production 
Next, we aimed to delineate whether 
the EVs hold the immunosuppressive 
potential described for MSCs paracrine 
secretion. Thus, the three distinct pools of 
SEC fractions were compared by their ability 
to modify the T cell response. Additional 
controls included CM and its concentrated 
(CCM) and eluted (ECM) products after 
ultrafiltration (Figure 3A). Also, the UC 
pellet from CM was compared to SEC-EVs. 
Only the SEC fractions containing EVs 
inhibited proliferation of stimulated T cells 
when added to the culture (34% reduction) 
(Figure 3B). This reduction of T cell 
proliferation showed a dose-dependent 
profile (Figure S3A, S3B). Importantly, when 
either proximal or distal non-EV fractions 
were added to the culture, T cell proliferation 
remained unaltered (Figure 3B), similar to 
the addition of CCM, ECM and CM. 
Moreover, the UC pellet did not impair T cell 
proliferation (Figure 3C). Noticeably, neither 
did EVs obtained from IFNγ-primed 
UCMSCs (Figure S3A). Viability of T cells 
was not altered in any of the conditions, thus 
 
Figure 3. Only the pooled EV fraction reduced T cell polyclonal proliferation. A: The three 
different pooled SEC fractions: EV, proximal non-EV (“non-EV prox”) and distal non-EV fractions 
(“non-EV dist”) were analyzed for T cell proliferation suppression capacity compared to the CCM, 
ECM, full CM, and ultracentrifuged pellet (UC Pellet). B, C: Proliferation of T cells stimulated with 
anti-CD2/CD3/CD28 beads (10:1 ratio) was analyzed by CFSE loss in the presence of pooled 
UCMSC-EVs, proximal and distal non-EV fractions, CCM, ECM and CM (B) or the UC Pellet (C). 
Quantities were adjusted to 2.5x105 initial UCMSC. Bars represent proliferation relative to their 
PBS control. C, D: Viability of stimulated T cells assessed by FSC-A/SSC-A. Data represent means ± 
SD for seven (B, D) and four (C, E) independent experiments. Statistical differences are indicated for 
groups with p<0.05 by Kruskall-Wallis; #p<0.05 by Wilcoxon Signed Rank test (to the 100%); 
*p<0.05 and **p<0.01 by Mann-Whitney test. 
 





discarding a principal apoptosis-mediated effect on T 
cell inhibited proliferation (Figure 3D, 3E). Finally, as 
an additional control to ratify the action by 
UCMSC-EV, complete medium alone was processed 
following the same SEC workflow, and the derived 
fractions did not suppress T cell proliferation (data 
not shown). 
To further study the immunomodulatory effect 
of EVs, the cytokine profile of stimulated T cells was 
determined. Consistent with the reduced 
proliferation, no production of the pro-inflammatory 
cytokines IL-6, TNF-α or IFNγ nor IL-2, was observed 
in T cell cultures to which EVs were added. In sharp 
contrast, IL-6, TGFβ1, IL-17A and, to a lesser extent 
IFNγ, were highly produced in the presence of both 
proximal and distal non-EV fractions and CM (Figure 
4).  
 
Figure 4. Cytokines found in the supernatants of T cell proliferation assays corresponding to Figure 3 were analyzed by CBA (IL-2, IL-4, IL-6, IL-10, TNF-α, IFNγ, and IL-17A) 
and TGF-β1 ELISA. Bars represent means ± SD of seven (A) and four (B) independent experiments. Statistical differences are indicated for groups with *p<0.05 by 
Kruskall-Wallis; *p<0.05 and **p<0.01 by Mann-Whitney test. 






Figure 5. Concentrated EV and non-EV fractions but not CM inhibit T cell polyclonal 
proliferation. A: EV, proximal non-EV fractions and CM were vacuum-concentrated 
and checked for T cell proliferation suppression capacity. B: Proliferation of T cells 
stimulated with anti-CD2/CD3/CD28 beads (10:1 ratio) was analyzed by CFSE loss in 
the presence of vacuum-concentrated UCMSC-EVs, proximal non-EV fractions or 
CM. Quantities were adjusted to 2.5x105 initial UCMSC, and dosage dependency was 
studied diluting samples 1/2 and 1/10 in PBS. Bars represent means ± SD of 
proliferation relative to their PBS control, for three independent experiments. C: 
Viability of stimulated T cells assessed by FSC-A/SSC-A. Data represent means ± SD 
for five independent experiments. Statistical differences are indicated for groups with 
p<0.05 by Kruskall-Wallis; #p<0.01 by Wilcoxon Signed Rank test (to the 100%); 
*p<0.05 and **p<0.01 by Mann-Whitney test. 
 
To our surprise, addition of full CCM to T cells 
promoted a cytokine rush, fostering the secretion of 
all the cytokines studied (IL-2, IL-4, IL-6, IL-10, 
TNF-α, IFNγ, TGF-β1 and IL-17A). On the other hand, 
addition of the UC pellet to T cells also fostered the 
production of IL-6 and IL-17A, resembling, rather 
than to SEC-EVs, the cytokine profile of T cells 
stimulated with CM (Figure 4B). These 
pro-inflammatory cytokines were also found in 
supernatants from MSC:T cell cultures at high cell 
ratios (Figure S4). Of note, all cytokines were also 
determined in CCM, ECM and CM, showing values 
always below the cytokines found in T cell 
proliferation supernatants (Figure S5), thus indicating 
that cytokine production in stimulated T cell cultures 
can be attributed genuinely to T cells.  
Concentrated UCMSC-EVs further reduce T 
cell proliferation 
In order to discard the possibility of a “dilution 
effect” of culture medium (volume added from SEC 
fractions) as an important factor influencing T cell 
proliferation, similar experiments were set up using 
vacuum concentration of the pooled fractions to 
minimize culture medium dilution (1.05-fold instead 
of 2-fold) (Figure 5A). 
In these experimental conditions, concentrated 
EVs reduced polyclonal T cell proliferation more than 
a 60% (37.47% proliferation relative to control, Figure 
5B), compared to the 34% reduction in 
non-concentrated conditions (Figure 3B). Intriguingly, 
in some experiments T cell viability was affected 
when concentrated EVs were added to the culture, 
although this effect was not statistically significant 
(Figure 5C). All these effects were lost upon EV 
dilution, confirming the EV-mediated T cell inhibition 
(Figure 5B and Figure S3C).  
An unexpected result was to observe that the 
concentrated proximal non-EV fraction turned out to 
mildly reduce T cell proliferation in a dose-dependent 
manner (Figure 5B), a feature that was not seen before 
in non-concentrated samples. Nevertheless, when the 
cytokine profile of stimulated T cells was analyzed, an 
enormous production of IFNγ, IL-6 and TGF-β1 was 
uniquely detected in supernatants from T cells 
stimulated in the presence of the proximal non-EV 
fraction (Figure 6), alerting of a pro-inflammatory 
stimulation of T cells, a feature that was completely 
absent in T cells incubated with EVs. Moreover, in 
accordance to non-concentrated experiments, CM was 
unable to suppress T cell polyclonal activation (Figure 
5B).  
To summarize, these results indicate that only 
the isolated SEC-EV fraction managed to greatly 
immunosuppress polyclonal T cell activation, while 
non-EV fractions, CM and UC pellet surprisingly 
promoted an inflammatory milieu and Th17 
polarization of T cells. 





Effect of UCMSC-EVs on monocyte 
polarization 
We also explored the effect of the pooled SEC 
fractions and full CM in the skewing of monocyte 
polarization. In this setting, we used three different 
well-determined monocyte polarizing stimuli as 
positive controls [29,30]: LPS plus IFNγ as an 
inflammatory “M1” phenotype inducer, and IL-4 or 
IL-10 to generate anti-inflammatory “M2a” or “M2c” 
phenotypes, respectively. As expected, M1 
(LPS+IFNγ) macrophages highly increased CD80 
mRNA, showed mild changes in CD163, and 
downregulated the expression of CD206 (Figure 7A). 
These cells also produced high levels of TNF-α and 
IL-10 (Figure 7B). In sharp contrast, M2a (IL-4) and 
M2c (IL-10) monocytes did not undergo 
changes in CD80 while upregulated CD206. 
Only M2c (IL-10) also incremented CD163 
expression, and had IL-10 in supernatants 
(probably as carryover effect from the 
activation stimulus used). None of the 
M2-skewing stimuli induced the secretion of 
TNF-α (Figure 7B). 
We then analysed the capacity of 
UCMSCs media to skew monocyte 
polarization. Culture with UCMSC-EVs 
maintained monocytes in a non-activated state, 
as cells did not substantially modify the 
expression of CD80, CD163, CD206 or IL-10 
compared to the control (p>0.05 to 
non-activated monocytes). Moreover, no 
TNF-α was detected in supernatants, 
indicating that samples did not contain 
pro-inflammatory mediators. 
Conversely, the proximal non-EV fraction 
and CM induced the expression of CD163 and 
CD206, while not altering that of CD80, thus 
resembling an M2c(IL-10) polarization (Figure 
7A), although not relevant amounts of IL-10 
were detected (Figure 7B). Of note, some 
TNF-α could be found when the proximal 
non-EV fraction was added. 
Discussion 
In this study, we demonstrate that EVs 
isolated from UCMSCs by SEC strongly 
immunomodulate activated T cells in vitro. In 
particular, our results indicate that the 
SEC-purified EV fraction greatly abrogates 
polyclonal T cell proliferation and cytokine 
production in comparison with non-EV 
fraction, CM and UC pellet, which conversely 
result in an inflammatory T cell response and 
foster the Th17 polarization of T cells. 
Additionally, EVs do not induce monocyte 
polarization or cytokine secretion, but the 
non-EV fraction induces the expression of 
CD163 and CD206 and some production of 
TNF-α by monocytes. These findings not only 
increase the growing evidence confirming that 
EVs are an active component of MSC’s 
paracrine immunosuppressive function, but 
 
Figure 6. Non-EV fractions and CM induce an inflammatory response on stimulated T cells. 
Cytokines found in the supernatants of T cell proliferation assays corresponding to Figure 5 were 
analyzed by CBA (IL-2, IL-4, IL-6, IL-10, TNF-α and IFNγ) and TGF-β1 and IL-17 ELISA. Bars 
represent means ± SD of three independent experiments for IL-2, IL-4, IL-6, IL-10, TNF-α and 
IFNγ and five independent experiments for TGF-β1 and IL-17. Statistical differences are indicated 
for groups with *p<0.05, **p<0.01 and ***p<0.001 by One-way ANOVA with Tukey’s post hoc 
analysis. 





also highlight the importance of working with well 
purified EV preparations to specifically achieve this 
effect. 
MSCs have been described to suppress the 
immune response affecting T cell proliferation and 
polarization, to induce regulatory T cells, and to 
module Antigen Presenting Cells (APCs) [11,31–34]. 
In our settings, UCMSCs were confirmed to have 
potent suppressive capabilities on T cell proliferation, 
but whereas IFNγ conditioning enhances 
immunosuppressive functions of both bone marrow- 
and adipose tissue-derived MSCs [7,9,35], no 
differences were found comparing IFNγ-primed to 
non-primed UCMSCs. This observation could be 
explained by the intrinsic capacity of UCMSCs to 
suppress T cell proliferation at low ratios compared to 
other studies (1:240 MSC to T cells), which may 
indicate that these cells own already a potent 
modulatory capacity of the T cell response. Another 
explanation might be the lack of APCs in our 
experimental setting, which have been described to 
partially mediate T suppression induced by MSCs 
[36]. In line, MSCs have been described to modulate 
the immune response by polarizing monocytes 
towards a M2 phenotype, which would in turn further 
modulate inflammation [37]. In any case, our results 
confirmed that non-primed UCMSCs showed a high 
immunomodulatory capacity at low MSC:T cell ratios. 
Also in line with previous studies, IFNγ 
increased the expression of HLA-II molecules in 
UCMSCs [38–40], which may have detrimental effects 
in the allogeneic scenario. Expression of HLA-II 
molecules in MSCs would trigger the activation of the 
host’s innate immune system which in turn would 
impede their potential immunomodulatory effect. In 
fact, it has been suggested that the increased HLA 
expression in EVs from umbilical cord blood-derived 
MSCs after treatment with IFNγ may be responsible 
of the loss of their protective effect against ischemic 
acute kidney injury [31]. Given that our results 
suggest that non-primed UCMSCs are as potent as 
primed MSCs in regulating T cell responses, we 
would consider using non-primed cells in therapeutic 
approaches. 
 
Figure 7. UCMSC-EVs do not affect CD80, CD163 and CD206 polarization marker expression in monocytes, while the non-EV fraction and CM induce increased expression 
of CD163 and CD206. Monocytes were cultured for 48h with polarizing cytokines to induce an inflammatory M1 (LPS+IFNγ) or anti-inflammatory M2a (IL-4) and M2c (IL-10) 
phenotypes, or with the EV, proximal non-EV fractions or full CM. A: mRNA fold change of the M1 marker CD80 and M2 markers CD163 and CD206, as analyzed by real time 
PCR. Values are relative to 18S and expressed as a fold change to the PBS-treated monocytes in a log2 scale. B: Levels of TNF-α and IL-10 in the supernatants of monocytes as 
measured by ELISA. Data are expressed as mean + SD and account for two different UCMSC and four monocyte donors. Statistical differences are indicated for groups with 
*p<0.05 by Kruskall-Wallis; *p<0.05 by Mann-Whitney test. 





In the context of cell therapy, transplantation of 
MSCs to induce immune suppression and tissue 
regeneration has still some limitations. Such 
drawbacks include the right homing and implantation 
–which is impaired by the entrapment of cells in the 
lung barrier upon systemic administration [41,42]-, 
the possible change in phenotype of the infused cells 
-influenced by the initial inflammatory phase 
occurring after in vivo infusion of MSCs [43]-, the 
requirement of cell viability after transplantation and 
ease of storage and availability. The majority of these 
caveats could be overcome by using EVs, resulting in 
a number of reports describing their benefits [22,44]. 
As MSCs exert their function through both cell contact 
and soluble mechanisms, it is expected that higher 
concentrations of EVs would be needed to reach the 
same level of inhibition obtained using MSCs, as we 
observed in our results. However, in the context of 
cell-free therapeutic approaches it is of relevance that 
one of the paracrine mechanisms of T cell inhibition 
by MSCs is based on well-defined and effectively 
enriched MSC-derived EVs. 
Recent studies have shown that MSC-EV 
products can efficiently modulate inflammatory 
disorders in vivo, including rat and mouse models and 
also human clinical trials [17,21,45–47]. Yet, several 
controversial studies noticed reduced 
immunosuppressive functions of CM and EVs 
compared to their parental cells [26,27]. Nevertheless, 
most of the studies performed so far on MSC-EV 
effect in vitro and in vivo used ultracentrifugation or 
precipitation methods [47]. These methods lead to EV 
preparations containing high quantities of non-EV 
proteins [24,48,49], result in cytotoxicity [49] and 
might explain the incongruous results on EV effects. 
Importantly, our results highlight the need of using 
well characterized and efficiently purified EVs to 
obtain an optimal cell-free immunosuppressive 
product. 
Isolation of EVs from MSC-CM by SEC yielded 
highly purified EVs that could be easily detected not 
only by tetraspanin markers, but also the MSC 
markers CD73 and CD90, confirming previous 
observations [28,50,51]. Importantly, SEC ensured the 
separation of EVs from the bulk of protein and 
impurities found in CM, as confirmed by cryo-EM, as 
it has been widely demonstrated before using other 
complex fluids such as plasma or urine [49,52–55]. 
Stressing the importance of using a well-defined 
cell-free product, it was extremely relevant to observe 
that SEC-purified EVs significantly differ from the 
non-EV fractions, full CM, and UC pellet in their 
functional capabilities. While isolated EVs 
successfully suppressed T cell proliferation and 
concomitantly inhibited the induction of cytokine 
production in a dose dependent manner, the non-EV 
fraction, full CM, and UC pellet displayed completely 
divergent properties. Further concentration of 
purified EVs using vacuum concentration resulted in 
an enhanced reduction of T cell proliferation 
compared to the control situation. This effect may be 
partially explained by a reduced T cell viability, which 
has been described before as a possible mechanism 
used by MSCs to constrain T cell activation [56,57]. 
Nevertheless, in our hands, reduced T cell viability 
was highly dependent on the EV batch, and was not 
observed when EVs were further diluted. 
In sharp contrast, the non-EV fractions only 
reduced T cell proliferation when they were vacuum 
concentrated, but at the same time induced the 
production of high amounts of inflammatory IL-6 
combined with TGFβ1. These two cytokines –along 
with IL-1β and IL-23-, are involved in the generation 
of Th17 responses [58,59], and in fact we could find 
the induction of Th17 cells in all conditions except 
SEC-EVs. Th17 polarization is known to be the cause 
of exacerbated inflammatory disorders and especially 
detrimental for autoimmune diseases such as multiple 
sclerosis, rheumatoid arthritis or to mediate GvHD 
and allergies [58,60]. In line with these results, recent 
studies delineate how EV products obtained by 
ultracentrifugation could lead to immune cell 
activation via NFκB [61]. Moreover, high levels of IL-6 
are the cause of inflammatory diseases and also have 
been linked with the exacerbated activation of the 
immune response causing the cytokine-release 
syndrome, an unexpected dangerous side effect found 
in some cell therapy clinical trials [62–64]. 
Antigen Presenting Cells (APCs) may also be 
potential targets of the MSC regulatory effect. In this 
sense, monocytes have been claimed as necessary for 
Treg generation by MSCs and MSC-derived CM, 
through their skewing to an M2 phenotype [37,65] 
and secretion of IL-10 [66], a functional trait of M2 
monocytes [29,67]. In line with these results, both CM 
and the non-EV fractions induced the expression of 
the M2 markers CD163 and CD206 on monocytes, 
with marginal amounts of IL-10 detected in 
supernatants. However, monocytes cultured with the 
non-EV fraction produced some levels of TNF-α, 
which may be indicative of unwanted cell activation. 
In sharp contrast, monocytes cultured in the presence 
of EVs did not show polarization or cytokine 
secretion, thus proving to be clean of polarizing 
stimuli or inflammatory mediators. 
All these results strongly suggest the need to use 
well-defined, cell-free, highly purified EV products in 
therapeutic approaches, and put into further value the 
immunomodulatory role of SEC-derived EVs on T 
cells. Given the complexity of the immune response, 





in which many actors play fundamental roles, 
defining the specific effects of EVs and non-EV 
fractions on single cell populations is a fundamental 
step for the deciphering of the underlying 
mechanisms of EVs in the modulation of key players, 
such as T cells and monocytes.  
Conclusion 
In summary, the present study thoroughly 
characterizes the different fractions found in 
UCMSCs-CM in terms of immune modulation 
potential. We have proven the feasibility of a strategy 
based on SEC to effectively isolate nanosized EVs 
responsible at least in part of the genuine MSC 
immunomodulatory capacities. Most importantly, our 
results highlight the importance of purity and fine 
characterization of the EV product envisioned as a 
cell-free therapeutic approach to avoid unwanted 
inflammatory responses. In this sense, since EVs are 
apparently well-tolerated, their use paves the way for 
innovative and more efficient therapies based in 
nanomedicine avoiding the putative side effects 
associated to stem cell transplantation. Together with 
other potential uses such as targeting cell membranes, 
delivering bioactive molecules and being analyzed for 
biomarkers (i.e, theranostics), this natural source of 
nanoparticles may be crucial in future developments 
on nanomedicine. 
Materials and Methods 
UC collection, MSC isolation, culture and 
characterization 
The study protocols were approved by the 
Clinical Research Ethics Committee of our institution 
(Comitè Ètic d’Investigació Clínica, HuGTiP, Refs. 
CEIC: EO-10-016 and EO-12-022) and conformed to 
the principles outlined in the Declaration of Helsinki. 
With the consent of the parents, fresh umbilical cords 
(n= 10) were obtained after birth and maintained in 
phosphate-buffered saline buffer (PBS; Gibco Life 
Technologies/Invitrogen, Carlsbad, CA) 
supplemented with 5,000 U heparin (Sigma Aldrich, 
St. Louis, MO) and 1% penicillin/streptomycin 
(Gibco) before tissue processing to isolate MSCs. UCs 
(10 g) were sectioned into 3-6 mm3 pieces and 
carefully washed in PBS to eliminate residual blood 
contained in arteries and vein. During mechanical 
disruption, elimination of UC vein and 
subendothelium was achieved. Further procedures 
include two enzymatic disaggregations at 37ºC with 
gentle agitation and a filtration step using Falcon Cell 
Strainers (BD Biosciences, San Diego, CA) in order to 
release uniform cell suspensions. First digestion was 
conducted using Collagenase type-I (880 U/mL; 
Gibco) plus Hyaluronidase II (3,960 U/mL; Sigma 
Aldrich) for 60 min, followed by a second digestion 
using Trypsin-EDTA (0,125%; Gibco) plus DNase I 
(0.2 mg/mL; Roche Diagnostics, Mannheim, 
Germany) for 30 min. The supernatants from both 
digestions were mixed together and centrifuged at 
1,200 rpm for 10 min. Cell pellet was then 
resuspended in α-MEM (Sigma) supplemented with 
10% heat-inactivated Foetal Bovine Serum (FBS; Life 
Technologies, Carlsbad, CA), 2mM L-glutamine and 
1% penicillin/streptomycin (Gibco) and 5 µg/mL 
plasmocin (Invivogen, San Diego, CA). Adherent cells 
were maintained under standard culture conditions 
until third-passage cells, when cells were used to 
analyze their surface marker expression profile and 
multipotency, as previously described [68–70]. 
Cells were labelled with 7AAD for viability and 
the antibodies anti-CD73-PE, -CD90-PE-Cy7, 
-HLA-DR-APC-H7 or the corresponding IgG isotype 
control (all from BD) for immunophenotyping. 
Labelling was performed at room temperature for 15 
min, washed with FACSFlow 2% FBS and centrifuged 
at 400g for 5 min. Data was acquired in a Canto II flow 
cytometer (BD) and analysed by FlowJo v.X software 
(TreeStar, Ashland, OR). 
Generation of EV-depleted culture medium 
Complete culture medium was composed of 
α-MEM (Sigma Aldrich) or TexMACS (Miltenyi 
Biotech, Bergisch Gladbach, Germany) medium 
supplemented with 2mM L-Glutamine (Sigma 
Aldrich), 100U/ml Penicillin (Cepa S.L., Madrid, 
Spain), 100µg/ml Streptomycin (Normon 
Laboratories S.A., Madrid, Spain) and 10% (v/v) Heat 
Inactivated-FBS or Human platelet lysate (Lonza, 
Basel, Switzerland) for MSC and T cell culture, 
respectively. Plasmocin (5 µg/mL; Invivogen) was 
added for MSC culture. 
Culture medium was depleted of bovine/human 
EVs by ultracentrifugation of 2x complete medium in 
polypropylene ultracentrifugation tubes (Beckman 
coulter, Brea, CA) at 100,000g for 16 h (SW28 rotor, 
28000 rpm, adjusted k-Factor= 253.96). The 
supernatant was collected and filtered through a 0.22 
µm filter (Sarstedt, Germany) to sterilize the medium, 
which was finally diluted to 1x working concentration 
with αMEM/TexMACS medium alone for cell 
culture. 
EV isolation 
EVs were isolated from UCMSCs following the 
scheme in Figure 2A. For MSCs-CM generation, 5x106 
UCMSCs were seeded in bovine EV-depleted culture 
medium with or without 200 ng/ml (120 IU/ml) IFNγ 
(Peprotech; cat#300-02, Rocky Hill, NJ) when 





indicated. Supernatant was collected after 48 h and 
sequentially centrifuged at 400g for 5 min and at 
2,000g for 10 min to exclude cells and cell debris, 
respectively. This debris-cleared CM was then 
concentrated by 100 kDa ultrafiltration using Amicon 
Ultra (Millipore, Millerica MA) at 2,000g for 35 min, 
obtaining typically 250 µl concentrated CM (CCM). 
The eluted CM (ECM) was kept for additional 
experiments. 
UCMSC-EVs were then isolated from the CCM 
by SEC using a modification of the previously 
published method [54]. Briefly, 1 ml of Sepharose 
CL-2B (Sigma Aldrich) was extensively washed with 
PBS (Oxoid, Hampshire, UK) and packed in a 1-ml 
syringe (BD). A 100 µl sample of CCM was loaded 
into the column and 100µl fractions (up to 20) were 
collected immediately after loading. Protein elution 
was checked by reading absorbance at 280 nm of each 
fraction using Nanodrop (Thermo Scientific, San 
Diego, CA).  
In some experiments, CM was ultracentrifuged 
at 100,000g for 2 h (SW55Ti rotor, 32500 rpm, adjusted 
k-Factor= 138.67), and the UC pellet was used for 
comparative experiments. As a control, 15 ml of 
bovine EV-depleted culture medium alone was 
incubated and followed the same EV isolation 
procedure. All fractions were kept at 4ºC and used 
within 24h for in vitro experiments, or frozen 
(-1ºC/min) at -80ºC for NTA and cryo-EM analysis. In 
the indicated experiments, fractions were 
concentrated seven-fold by 90 min vacuum 
concentration at 30ºC using the miVac (GeneVac, 
Ipswich, UK).  
EV characterization 
Flow cytometry 
The presence of EVs in the SEC fractions was 
determined according to their content in tetraspanins 
by bead-based flow cytometry. Briefly, EVs were 
coupled to 4 µm aldehyde/sulphate-latex 
microspheres (Invitrogen, Carlsbad, CA) for 15 
minutes at RT and blocked in BCB buffer (PBS/0.1% 
BSA/0.01% NaN3; both from Sigma Aldrich) on 
overnight rotation. EV-coated beads were spun down 
at 2000g for 10 min, washed with BCB buffer and 
re-suspended in PBS. 
EV-coated beads were then labelled with the 
fluorochrome-conjugated antibodies anti-CD73-PE, 
-CD90-PE-Cy7, -HLA-ABC-FITC or 
-HLA-DR-APC-H7 (all from BD) or indirectly labelled 
with the primary antibodies anti-CD9 (Clone VJ1/20) 
and -CD63 (Clone TEA3/18) or the IgG isotype 
control (Abcam, Cambridge, UK) and secondary 
antibody FITC-conjugated Goat F(ab')2 Anti-Mouse 
IgG (Bionova, Halifax, NS, Canada). Labelling was 
performed at room temperature for 30 min under 
mild shaking, and EV-coupled beads were washed 
after each step with BCB buffer and centrifuged at 
2,000g for 10 min. Data was acquired in a FACSVerse 
flow cytometer (BD) and analysed by FlowJo v.X 
software (TreeStar). 
Nanoparticle Tracking Analysis 
Size distribution of particles on SEC fractions 
was determined by NTA in a NanoSight LM10-12 
instrument (Malvern Instruments Ltd, Malvern, UK), 
equipped with a 638 nm laser and CCD camera 
(model F-033). Data was analyzed with the NTA 
software version 3.1. (build 3.1.46), with detection 
threshold set to 5, and blur, Min track Length and 
Max Jump Distance set to auto. Samples were diluted 
10 or 20 times with PBS to reach optimal concentration 
for instrument linearity: 20-120 particles/frame as 
advised by the manufacturer. Readings were taken on 
triplicates of 60 s at 30 frames per second, at a camera 
level set to 16 and with manual monitoring of 
temperature. 
Cryo-electron microscopy 
SEC fractions were examined for EV size and 
morphology by cryo-electron microscopy (cryo-EM). 
Vitrified specimens were prepared by placing 3 μl of a 
sample on a Quantifoil® 1.2/1.3 TEM grid, blotted to 
a thin film and plunged into liquid ethane-N2(l) in the 
Leica EM CPC cryoworkstation (Leica, Wetzlar, 
Germany). The grids were transferred to a 626 Gatan 
cryoholder and maintained at -179ºC. Samples were 
analyzed with a Jeol JEM 2011 transmission electron 
microscope (Jeol, Tokyo, Japan) operating at an 
accelerating voltage of 200 kV. Images were recorded 
on a Gatan Ultrascan 2000 cooled charge-coupled 
device (CCD) camera with the Digital Micrograph 
software package (Gatan, Pleasanton, CA).  
Proliferation assay 
Whole blood was obtained from healthy donors 
after informed consent approved by the local Ethics 
Committee (Germans Trias i Pujol Universitary 
Hospital). PBMCs were obtained by Ficoll Hypaque 
PlusTM (GE Healthcare, Uppsala, Sweden) density 
centrifugation and T cells were then isolated using the 
negative selection EasySepTM Human T cell 
Enrichment Kit (StemCell Technologies, Grenoble, 
France) following manufacturer’s instructions. 
Enriched T cells were then washed and stained with 
Carboxyfluorescein succinimidyl ester (CFSE, 
Molecular Probes, Leiden, The Netherlands) to assess 
cell proliferation. Succinctly, enriched T cells were 
resuspended in PBS for staining with an equal volume 
of 0.8µM CFSE for 10 minutes, after which unbound 
dye was quenched with RPMI + 10% FBS. Labeled 





cells were washed twice with RPMI + 10% FBS before 
resuspending in 1x human EV-depleted TexMACS 
complete medium. T cells were routinely >93% pure 
(CD3+) and >94% viable in all experiments performed. 
CFSE-labeled T cells (3·105) were stimulated with 
anti-CD2/CD3/CD28 coated microbeads (Pan T Cell 
Activation Kit; Miltenyi Biotech) or uncoated 
microbeads as a negative control in a 1:10 bead:T cell 
ratio, in flat-bottomed well plates in which allogeneic 
UCMSCs had been previously seeded (20000, 5000, 
1250, 625, 325 or 160 cells/well). In parallel 
experiments, CFSE-labeled T cells were plated at 5·104 
cells/well in round-bottomed well plates and 
stimulated in the same way with 
anti-CD2/CD3/CD28 coated microbeads. T cells were 
co-cultured in the presence of 1:1 or 1:2 (v/v) EV, 
proximal or distal non-EV fractions, CCM, ECM or 
CM, corresponding to 2.5x105 or 1.25x105 initial 
UCMSCs, respectively. Alternatively, 1:20 (v/v) 
vacuum concentrated samples were added to 
stimulated T cells, corresponding to 2.5x105, 1.25x105 
(1/2 dilution) or 2.5x104 (1/10 dilution) initial 
UCMSCs. T cell proliferation was measured after 3.5 
days in a LSR Fortessa Analyzer (BD Biosciences) and 
expressed as the percentage of FSChighCFSElow cells 
out of the living cells gated by FSC/SSC using the 
proliferation module of the FlowJo V9.8.2. 
Monocyte polarization 
PBMCs were obtained from leukocyte residues 
from healthy donors from the Blood and Tissue Bank 
(Barcelona, Spain) by Ficoll Hypaque PlusTM density 
gradient centrifugation (GE Healthcare Biosciences), 
and CD3+ cells were depleted using the RosetteSepTM 
Human CD3 Depletion Cocktail (StemCell 
Technonogies). Monocytes were then isolated using 
the MagniSort Human CD14 Positive Selection kit 
(eBioscience) according the instructions supplied by 
manufacturer. Recovered cells were counted using 
PerfectCount Microspheres (Cytognos, Salamanca, 
Spain) and assessed for purity (>93% CD14+) and 
viability (≥97% by FSC/SSC and 7AAD- (BD) gating) 
in a Canto II flow cytometer (BD). 
Monocytes were plated at 1·106cells/ml in RPMI 
medium containing 5% FBS and the polarizing stimuli 
for M1(LPS+IFNγ), 50ng/mL IFNγ (Preprotech) plus 
100ng/mL LPS from E. coli O111:B4 (Sigma-Aldrich); 
M2a(IL-4), 40 ng/ml IL-4 (Preprotech); M2c(IL-10), 50 
ng/ml IL-10 (Preprotech), or with the EV, proximal 
non-EV fractions or full CM, and PBS alone 
(non-activated control). After 48h, the supernatant 
was harvested for cytokine determination and whole 
RNA was extracted from cells using the RNeasy Mini 
Kit (Qiagen). cDNA was synthesized using random 
hexamers (Qiagen) and the iScriptTM One-Step 
RT–PCR Kit (BioRad Laboratories) according to 
supplier’s protocol. Each cDNA was then amplified in 
a LightCycler® 480 PCR system (Roche Life Science) 
using the KAPA SYBR Fast Master Mix (KAPA 
Biosystems). Samples were incubated for an initial 
denaturation at 95°C for 5 min, and then 40 PCR 
cycles were performed at 95°C for 10 s, 60°C for 20 s 
and 72°C for 10 s. The values obtained by the “Fit 
point” method were correlated to a standard curve 
and normalized to the expression levels of the 
endogenous reference gene 18S. The gene expression 
levels of each stimulus were calculated as a fold 
change relative to non-activated monocytes.  
Measurement of cytokine production 
Cytokines present in supernatants from 
alloproliferation assays collected at day 3.5 were 
measured using the CBA human Th1/Th2 or the 
Th1/Th2/Th17 Cytokine kit (both from BD 
Biosciences), the TGF-β1 ELISA (eBioscience, San 
Diego, CA) and IL-17 ELISA (U-CyTech, Utrecht, The 
Netherlands) following manufacturer’s instructions. 
Cytokines present in supernatants of 48h-cultured 
monocytes were measured using the human IL-10 and 
TNF-α ELISA (U-CyTech). Concentrations given by 
CBA were assessed in a LSR Fortessa Analyzer (BD) 
and concentrations of ELISA determinations in a 
Varioskan LUX multimode microplate reader 
(Thermo Scientific). The minimum detectable 
concentration (pg/ml) of each protein was 2.6 for IL-2 
and IL-4, 3.0 for IL-6, 2.8 for IL-10 and TNF-α, 7.1 for 
IFNγ, 8 for TGF-β1, 2 for IL-17 and 1 for IL-10 and 
TNF-α. 
Statistical Analysis 
Values are expressed as mean ± standard 
deviation (SD). Kolmogorov-Smirnov analysis was 
used to check for normality of data. ANOVA one-way 
with Tukey’s post-hoc analysis was applied to 
determine significance among more than two groups 
of parametric data. Paired T test and Wilcoxon 
matched-pairs signed rank test were used to analyze 
differences between two paired parametric and 
non-parametric data groups, respectively. 
Kruskall-Wallis analysis was used to determine 
significance among groups and Mann-Whitney test to 
find differences between two groups of 
non-parametric data. One sample T test and Wilcoxon 
Signed Rank test were used to determine differences 
of normalized parametric and non-parametric data, 
respectively. Analyses were performed using the 
GraphPad Prism software (6.01 version) and the SPSS 
statistic software (19.0.1 version, SPSS Inc., Chicago, 
IL), and differences were considered significant when 
p<0.05. 
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